- Home
- IMXI vs DMAC Comparison
IMXI vs DMAC Comparison
Compare IMXI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMXI
- DMAC
- Stock Information
- Founded
- IMXI 1994
- DMAC 2000
- Country
- IMXI United States
- DMAC United States
- Employees
- IMXI N/A
- DMAC N/A
- Industry
- IMXI Retail: Computer Software & Peripheral Equipment
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- IMXI Technology
- DMAC Health Care
- Exchange
- IMXI Nasdaq
- DMAC Nasdaq
- Market Cap
- IMXI 302.5M
- DMAC 260.0M
- IPO Year
- IMXI N/A
- DMAC N/A
- Fundamental
- Price
- IMXI $9.38
- DMAC $4.48
- Analyst Decision
- IMXI Buy
- DMAC Strong Buy
- Analyst Count
- IMXI 7
- DMAC 4
- Target Price
- IMXI $19.60
- DMAC $10.75
- AVG Volume (30 Days)
- IMXI 328.5K
- DMAC 426.7K
- Earning Date
- IMXI 08-15-2025
- DMAC 08-15-2025
- Dividend Yield
- IMXI N/A
- DMAC N/A
- EPS Growth
- IMXI 1.60
- DMAC N/A
- EPS
- IMXI 1.70
- DMAC N/A
- Revenue
- IMXI $652,547,000.00
- DMAC N/A
- Revenue This Year
- IMXI N/A
- DMAC N/A
- Revenue Next Year
- IMXI $2.93
- DMAC N/A
- P/E Ratio
- IMXI $5.42
- DMAC N/A
- Revenue Growth
- IMXI N/A
- DMAC N/A
- 52 Week Low
- IMXI $8.58
- DMAC $3.19
- 52 Week High
- IMXI $22.37
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- IMXI 42.96
- DMAC 60.47
- Support Level
- IMXI $8.58
- DMAC $4.01
- Resistance Level
- IMXI $9.57
- DMAC $5.09
- Average True Range (ATR)
- IMXI 0.34
- DMAC 0.36
- MACD
- IMXI 0.03
- DMAC 0.01
- Stochastic Oscillator
- IMXI 47.18
- DMAC 54.90
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.